[Experimental studies on hepatic cancer chemo-embolization].
Mitomycin microspheres (MMC MS), which contain about 5% of MMC and have an average diameter of 45 +/- 8 microns, were administered into the rat hepatic artery in a preclinical study on antitumor treatment for human hepatic cancer. Plasma GOT and GPT activities increased markedly 24 hours after MMC MS injection; they decreased to within the normal range within 3 days of the injection. Hepatic necrobiosis was observed in the area adjacent to the hepatic arterioles containing MMC MS, but was not observed in rats injected with placebo microspheres. The hepatic vein blood of MMC MS treated rats contained a markedly high level of MMC, compared to rats treated in the conventional fashion with MMC. Furthermore, MMC MS remained within hepatic arterioles for over 3 weeks.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D004621:Embolization, Therapeutic; D006499:Hepatic Artery; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D008863:Microspheres; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D051381:Rats; D011919:Rats, Inbred Strains
D008937:Mitomycins; D016685:Mitomycin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase